| Catalog: | C-FC-2826A |
| Product Type: | FCM Antibody |
| Size: | 25 Tests/100 Tests |
| Concentration: | 10 μl/Test, 0.1 mg/ml |
| Reactivity: | Human |
| Specificity: | Human B7-1 |
| Analysis mode: | FCM |
| Host: | Mouse |
| Clonality: | Monoclonal |
| Isotype: | IgG1 |
| Alternate names: | CD80 molecule |
| Form: | Liquid |
| Shipping: | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage: | This antibody can be stored at 2℃-8℃ for twelve months without detectable loss of activity. Protected from prolonged exposure to light. Do not freeze ! Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal. |
| Purification method: | Protein A |
| Conjugation: | FITC |
| Immunogen: | Recombinant Human CD80 / B7-1 Protein |
| Buffer: | Aqueous solution containing 0.5% BSA and 0.09% sodium azide |
| Application: | Cancer Drug Targets |
The B-lymphocyte activation antigen B7-1 (referred to as B7), also known as CD80, is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. As costimulatory ligands, B7-1 which exists predominantly as dimer and the related protein B7-2, interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus constitute one of the dominant pathways that regulate T cell activation and tolerance, cytokine production, and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.
Copyright © 2025 Creative Biogene. All rights reserved.